The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Zymeworks BC Inc (NASDAQ: ZYME) closed at $12.35 in the last session, down -3.52% from day before closing price of $12.80. In other words, the price has decreased by -$3.52 from its previous closing price. On the day, 0.65 million shares were traded. ZYME stock price reached its highest trading level at $12.75 during the session, while it also had its lowest trading level at $12.15.
Ratios:
We take a closer look at ZYME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.40 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On November 07, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $10 to $25.
Wells Fargo Downgraded its Overweight to Equal Weight on November 01, 2024, while the target price for the stock was maintained at $12.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 20 ’25 when EcoR1 Capital, LLC bought 73,476 shares for $12.93 per share. The transaction valued at 949,883 led to the insider holds 17,104,080 shares of the business.
EcoR1 Capital, LLC bought 31,033 shares of ZYME for $396,518 on Mar 21 ’25. The Director now owns 17,135,113 shares after completing the transaction at $12.78 per share. On Mar 24 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 22,689 shares for $13.08 each. As a result, the insider paid 296,847 and bolstered with 17,157,802 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 890584384 and an Enterprise Value of 652032512. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.35 while its Price-to-Book (P/B) ratio in mrq is 2.53. Its current Enterprise Value per Revenue stands at 8.545 whereas that against EBITDA is -5.769.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.16, which has changed by 0.24271846 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is -9.40%, while the 200-Day Moving Average is calculated to be -1.37%.
Shares Statistics:
According to the various share statistics, ZYME traded on average about 524.38K shares per day over the past 3-months and 735330 shares per day over the past 10 days. A total of 68.96M shares are outstanding, with a floating share count of 67.30M. Insiders hold about 4.07% of the company’s shares, while institutions hold 97.32% stake in the company. Shares short for ZYME as of 1741910400 were 5415327 with a Short Ratio of 10.33, compared to 1739491200 on 3837127. Therefore, it implies a Short% of Shares Outstanding of 5415327 and a Short% of Float of 10.100000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
